The article by Di Federico et al titled “Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations” (JCO Precis Oncol ...
The FDA has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and only subcutaneous, chemo-free ...
The FDA accepted an application for ivonescimab with chemotherapy for patients with lung cancer driven by EGFR changes after prior targeted treatment.
A groundbreaking phase 2 clinical trial has unveiled promising advancements in the treatment landscape for non-small cell lung cancer (NSCLC), ...
Ivonescimab's BLA acceptance is a milestone for PD-1/VEGF bispecific antibodies in the U.S., potentially transforming second-line NSCLC treatment post-TKI failure. The HARMONi trial showed ivonescimab ...
Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion pursuits in five therapeutic settings ripe for next-gen innovation.
Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion pursuits in five therapeutic settings ripe for next-gen innovation.
The National Comprehensive Cancer Network’s newly updated non-small cell lung cancer guideline adds sevabertinib as a treatment option for some patients with advanced disease, makes datopotamab ...
A newly published scientific paper titled "Gene Expression Patterns in Lung Adenocarcinoma Cells in Response to Changes in ...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that a new indication ...
Summit Therapeutics has moved ahead in the race to bring a therapy targeting both VEGF and PD- (L)1 to market, after the FDA started a review of its ivonescimab drug for lung cancer.
As smoking rates fall, lung cancer in never-smokers (LCINS) represents an increasing share of lung cancer diagnoses. These cancers are frequently detected at a late stage, when they are less treatable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results